Abdul leads Healthcare consulting practice at BIS Research on strategic and operational activities, focusing on market research and competitive intelligence. Abdul brings nearly 8 years of strategic consulting and operational experience in the life sciences industry. He has co-authored and supervised more than 200 market research projects across the biopharmaceutical industry. Prior to joining BIS Research, Abdul was a Sr. Research Analyst at TMR Group where he developed strategies for biopharmaceutical, medical device, and digital health companies to drive innovation and growth across a diverse set of business challenges including R&D and launch strategy, portfolio optimization, and organizational effectiveness. Before his time at TMR Group, Abdul has also worked with prominent companies such as e4e Healthcare Services, and, Salient Business Solutions as an analyst, where he worked on a range of topics, including entering new markets, utilizing novel data and analytics, and sales forecasting.
Clinical & Research Tools Showcase:
BIS Research, Inc.
BIS Research is a leading global market intelligence, research, and advisory company that focuses on those emerging trends in technology which are likely to disrupt the dynamics of the market. BIS Research publishes comprehensive global market research reports across different industry verticals.
Liquid Biopsy: Current State and Future Directions
Insight and foresight around emerging Liquid Biopsy applications for early cancer screening, market potential, and future outlook, competitive landscape, challenges of Liquid Biopsy in cancer monitoring and treatment, and winning strategies for emerging Liquid Biopsy companies.
The PMWC 2022 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.